National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 77625-77626 [2022-27426]
Download as PDF
<![CDATA[
tkelley on DSK125TN23PROD with NOTICE
Federal Register / Vol. 87, No. 242 / Monday, December 19, 2022 / Notices
Date: March 2, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W608, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Nadeem Khan, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W608, Rockville, Maryland
20850, 240–276–5856, nadeem.khan@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Patient
Derived Xenograft (PDX) Development and
Trial Centers (PDTCs) Network (U54 and
U24).
Date: March 2–3, 2023.
Time: 10:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Byeong-Chel Lee, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W238, Rockville, Maryland 20850,
240–276–7755, byeong-chel.lee@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–1:
SBIR Contract Review: Development of
Senotherapeutic Agents for Cancer
Treatment.
Date: March 8, 2023.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W246, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, Maryland 20850,
240–276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–2:
SBIR Contract Review.
Date: March 9, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W106, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Eduardo Emilio Chufan,
Ph.D., Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W106, Rockville, Maryland
20850, 240–276–7975, chufanee@
mail.nih.gov.
VerDate Sep<11>2014
19:38 Dec 16, 2022
Jkt 259001
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Research Specialist (Clinical Scientist)
Award (R50).
Date: March 10, 2023.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W242, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Zhiqiang Zou, M.D., Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W242, Rockville,
Maryland 20850, 240–276–6372, zouzhiq@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–4: NCI
Clinical and Translational Cancer Research.
Date: March 15, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W618, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: E. Tian, Ph.D., Scientific
Review Officer, Research Program Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room7W618, Rockville,
Maryland 20850, 240–276–6611, tiane@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–9: NCI
Clinical and Translational Cancer Research.
Date: March 22, 2023,
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W634, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Michael E. Lindquist,
Ph.D., Scientific Review Officer, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W634, Rockville, Maryland 20850,
mike.lindquist@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–3: NCI
Clinical and Translational Cancer Research.
Date: March 23, 2023.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W126, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W126,
Rockville, Maryland 20850, 240–276–6611,
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–1: NCI
Clinical and Translational Cancer Research.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
77625
Date: March 29, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W110, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Caterina Bianco, M.D.,
Ph.D., Chief, Scientific Review Officer,
Resources and Training Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W110, Rockville, Maryland
20850, 240–276–6459, biancoc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: December 13, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27417 Filed 12–16–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
SBIR Contract Review.
Date: January 24, 2023.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6705
Rockledge Drive, Bethesda, MD 20817
(Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
E:\FR\FM\19DEN1.SGM
19DEN1
77626
Federal Register / Vol. 87, No. 242 / Monday, December 19, 2022 / Notices
6705 Rockledge Drive, Room 205–J,
Bethesda, MD 20892, (301) 827–7085,
zhihong.shan@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: December 13, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27426 Filed 12–16–22; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
tkelley on DSK125TN23PROD with NOTICE
Name of Committee: National Institute on
Aging Special Emphasis Panel; Genetic
Variation and Aging.
Date: January 31, 2023.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Aging Gateway
Building, 7201 Wisconsin Avenue, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Greg Bissonette, Ph.D.
Scientific Review Officer, National Institute
of Aging, National Institute of Health,
Gateway Building, Suite 2W200, 7201
Wisconsin Avenue, Bethesda, MD 20892,
301–402–1622, bissonettegb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 13, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27421 Filed 12–16–22; 8:45 am]
BILLING CODE 4140–01–P
19:38 Dec 16, 2022
U.S. Customs and Border Protection
[1651–0098]
NAFTA Regulations and Certificate of
Origin
U.S. Customs and Border
Protection (CBP), Department of
Homeland Security.
ACTION: 60-Day notice and request for
comments; extension of an existing
collection of information.
AGENCY:
The Department of Homeland
Security, U.S. Customs and Border
Protection will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (PRA). The
information collection is published in
the Federal Register to obtain comments
from the public and affected agencies.
DATES: Comments are encouraged and
must be submitted no later than
February 17, 2023 to be assured of
consideration.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice must include
the OMB Control Number 1651–0098 in
the subject line and the agency name.
Please use the following method to
submit comments:
Email. Submit comments to: CBP_
PRA@cbp.dhs.gov.
Due to COVID–19-related restrictions,
CBP has temporarily suspended its
ability to receive public comments by
mail.
FOR FURTHER INFORMATION CONTACT:
Requests for additional PRA information
should be directed to Seth Renkema,
Chief, Economic Impact Analysis
Branch, U.S. Customs and Border
Protection, Office of Trade, Regulations
and Rulings, 90 K Street NE, 10th Floor,
Washington, DC 20229–1177, telephone
number 202–325–0056 or via email
CBP_PRA@cbp.dhs.gov. Please note that
the contact information provided here is
solely for questions regarding this
notice. Individuals seeking information
about other CBP programs should
contact the CBP National Customer
Service Center at 877–227–5511, (TTY)
1–800–877–8339, or CBP website at
https://www.cbp.gov/.
SUPPLEMENTARY INFORMATION: CBP
invites the general public and other
Federal agencies to comment on
proposed and/or continuing information
collections pursuant to the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
DEPARTMENT OF HOMELAND
SECURITY
Jkt 259001
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
et seq.). This process is conducted in
accordance with 5 CFR 1320.8. Written
comments and suggestions from the
public and affected agencies should
address one or more of the following
four points: (1) whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility; (2) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
suggestions to enhance the quality,
utility, and clarity of the information to
be collected; and (4) suggestions to
minimize the burden of the collection of
information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology, e.g., permitting
electronic submission of responses. The
comments that are submitted will be
summarized and included in the request
for approval. All comments will become
a matter of public record.
Overview of This Information
Collection
Title: NAFTA Regulations and
Certificate of Origin.
OMB Number: 1651–0098.
Form Number: 434, 446, and 447.
Current Actions: This submission is
being made to extend the expiration
dates for CBP Forms 434, 446, and 447
with no change to the estimated burden
hours or to the information collected.
Type of Review: Extension (without
change).
Affected Public: Businesses.
Abstract: On December 17, 1992, the
U.S., Mexico and Canada entered into
an agreement, the North American Free
Trade Agreement (NAFTA). The
provisions of NAFTA were adopted by
the U.S. with the enactment of the North
American Free Trade Agreement
Implementation Act of 1993 (Pub. L.
103–182, 107 Stat. 2057).
CBP Form 434, North American Free
Trade Agreement Certificate of Origin, is
used to certify that a good being
exported either from the United States
into Canada or Mexico or from Canada
or Mexico into the United States
qualifies as an originating good for
purposes of preferential tariff treatment
under NAFTA. This form is completed
by exporters and/or producers and
furnished to CBP upon request. CBP
Form 434 is provided for by 19 CFR
181.11, 181.22, and is accessible at:
https://www.cbp.gov/newsroom/
publications/forms.
E:\FR\FM\19DEN1.SGM
19DEN1
]]>Agencies
[Federal Register Volume 87, Number 242 (Monday, December 19, 2022)]
[Notices]
[Pages 77625-77626]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27426]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; SBIR Contract Review.
Date: January 24, 2023.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6705 Rockledge Drive,
Bethesda, MD 20817 (Virtual Meeting).
Contact Person: Zhihong Shan, Ph.D., MD, Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
[[Page 77626]]
6705 Rockledge Drive, Room 205-J, Bethesda, MD 20892, (301) 827-
7085, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: December 13, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-27426 Filed 12-16-22; 8:45 am]
BILLING CODE 4140-01-P
